NAChR Alpha-4 Beta-4: AG Protein-coupled Receptor for Neurological and Psychiatric Disorders

Target Name: Nicotinic alpha4beta4 receptor

NCBI ID: P32669

Nicotinic alpha4beta4 receptor

Other Name(s): nAChR alpha4beta4

NAChR Alpha-4 Beta-4: AG Protein-coupled Receptor for Neurological and Psychiatric Disorders

The Nicotinic acid alpha-4 (alpha-4) beta-4 (NAChR alpha-4 beta-4) receptor is a G protein-coupled receptor that plays a crucial role in various physiological processes in the body. It is expressed in various tissues, including the brain, heart, and muscles, and is involved in the regulation of a wide range of physiological processes, including pain perception, inflammation, and neurotransmitter signaling.

Recent studies have identified NAChR alpha-4 beta-4 as a potential drug target and biomarker for various neurological and psychiatric disorders, including chronic pain, anxiety and depression. The alpha-4尾-4 receptor is also a promising target for the development of non-opioid pain relief drugs.

The NAChR alpha-4 beta-4 receptor is a member of the G protein-coupled receptor family, which includes over 700 different receptors that play a crucial role in various physiological processes in the body. G protein-coupled receptors are involved in the regulation of a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and cellular signaling.

The NAChR alpha-4 beta-4 receptor is expressed in various tissues, including the brain, heart, and muscles, and is involved in the regulation of a wide range of physiological processes. Image: Pixabay

The NAChR alpha-4 beta-4 receptor is involved in the regulation of pain perception and neurotransmitter signaling. Studies have shown that NAChR alpha-4 beta-4 is involved in the regulation of pain perception and neurotransmitter signaling, including the production and release of endogenous opioids, such as enkeji and endorphins.

In addition to its role in pain perception and neurotransmitter signaling, the NAChR alpha-4 beta-4 receptor is also involved in the regulation of other physiological processes, including inflammation and cellular signaling. For example, studies have shown that NAChR alpha-4 beta-4 is involved in the regulation of inflammation in the brain, and that it plays a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

The NAChR alpha-4 beta-4 receptor is also a potential drug target and biomarker for various neurological and psychiatric disorders. Studies have shown that the NAChR alpha-4 beta-4 receptor is involved in the regulation of anxiety and depression, and that it may be a useful target for the development of non-opioid pain relief drugs.

In addition to its potential as a drug target and biomarker, the NAChR alpha-4 beta-4 receptor is also a promising target for the development of other therapeutic compounds. For example, studies have shown that the NAChR alpha-4 beta-4 receptor is involved in the regulation of cellular signaling, and that it may be a useful target for the development of compounds that can modulate its activity.

Overall, the NAChR alpha-4 beta-4 receptor is a G protein-coupled receptor that plays a crucial role in various physiological processes in the body. Its potential as a drug target and biomarker for various neurological and psychiatric disorders makes it an attractive target for further research and development.

Protein Name: Nicotinic Alpha4beta4 Receptor

The "Nicotinic alpha4beta4 receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Nicotinic alpha4beta4 receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets